Funding and other support from private organizations and philanthropists has helped keep many medical researchers at the forefront of their fields, which has resulted in some cases in longer life expectancies and a higher quality of life for people affected by certain diseases. To help ensure science funding pipelines continue to be robust—and to help train the next generation of researchers—nonprofit biomedical funding organizations should pay close attention to the changing nature of giving.Read more
Filter by category or month:
For a life sciences industry whose Research & Development (R&D) processes are often held over from the 1990s—and whose returns on those investments are falling sharply—new digital technologies might feel as if they can’t arrive fast enough.
Almost everywhere you turn, there seems to be an opportunity as outlined in Deloitte’s recent report,Read more
The Deloitte Center for Health Solutions recently interviewed 43 biopharmaceutical industry stakeholders to explore where the industry sees value and opportunities for using digital technologies in the clinical development process; understand reasons behind the relatively slow pace of digital adoption; and uncover strategies to overcome barriers and accelerate the use of digital in clinical trials.Read more
This week Deloitte and the National Institutes of Health’s National Library of Medicine (NLM) will recognize two student-led research teams from San Diego State University (SDSU) and Kingsborough Community College of The City University of New York (KCC CUNY) for their groundbreaking research in the Microbial Metagenomics Discovery Challenge.
The undergraduate students’ work was impressive by any standard.Read more
This week, we will witness liftoff for a new National Institutes of Health (NIH) initiative that strives to move our current state of research to a future state of precision medicine where data is broken out of siloes. Researchers will have novel opportunities to study the data, which could speed medical breakthroughs.
I’ve had the privilege of seeing the All of Us Research Program grow from a kernel of an idea into a path-breaking program that ambitiously aims to gather data from 1 million or more diverse people—healthy and sick—living in the US.Read more
Expanding Medical Affairs could help restore trust, demonstrate value of biopharma organizations and productsby Tom Yang, Principal, Monitor Deloitte, Deloitte Consulting, LLP
Within biopharmaceutical companies, Medical Affairs has often been seen as a necessity, but not necessarily core. This unit is typically neither responsible for the development nor commercialization of new drugs.
We see untapped value in Medical Affairs for biopharma, but few companies have been able to capture it. Here are three areas where Medical Affairs could enhance value for biopharma companies:
- Restoring trust: In an environment that has commonly grown skeptical of large biopharma companies,